论文部分内容阅读
目的:探讨索拉非尼对晚期肝癌的治疗效果。方法:回顾性分析32例无法手术切除的原发性肝细胞癌(HCC)患者口服索拉非尼治疗的临床资料。分析患者的一般资料、肿瘤进展时间及毒性反应。结果:32例患者给予连续口服索拉非尼,常规剂量为每次400 mg,每天2次;按照RECIST标准评价有效率(RR)9.3%,疾病控制有效率(DCR)78.1%。中位肿瘤进展时间(TTP)8个月。全组患者均出现手足皮肤反应,21例出现不同程度腹泻,15例出现脱发,3例高血压,其中5例发生3~4级的不良反应而减少药物剂量,经对症治疗后好转。结论:索拉非尼是治疗晚期肝细胞癌的有效、安全的药物,联合TACE能取得更好的临床疗效。
Objective: To investigate the therapeutic effect of sorafenib on advanced liver cancer. Methods: The clinical data of 32 patients with unresectable primary hepatocellular carcinoma (HCC) who underwent oral sorafenib treatment were retrospectively analyzed. Analyze the patient’s general information, tumor progression time and toxicity. RESULTS: Twenty-three patients received continuous oral sorafenib at a dose of 400 mg twice daily, with a response rate of 9.3% and a disease-control effective rate (DCR) of 78.1% according to RECIST criteria. Median tumor progression time (TTP) 8 months. All patients had hand-foot skin reactions, 21 cases of varying degrees of diarrhea, 15 cases of hair loss, 3 cases of hypertension, 5 cases occurred 3 to 4 adverse reactions and reduce the dose of drugs, after symptomatic treatment improved. Conclusion: Sorafenib is an effective and safe drug for the treatment of advanced hepatocellular carcinoma. TACE can achieve better clinical efficacy.